Table 1.
Baseline characteristics of the cohorts
| All subjects n = 97 | Normal mucosa (Marsh stage 0) n = 39 | Lymphocytic enteritis (Marsh stage 1) n = 58 | P | |
|---|---|---|---|---|
| Demographic characteristics | ||||
| Females, n (%) | 86 (89) | 34 (87) | 52 (90) | 0.959 |
| Age in years, mean (SD) | 50 (8) | 49 (7) | 51 (9) | 0.222 |
| BMI, kg/m 2 , mean (SD) | 26 (4) | 25 (3) | 28 (5) | <0.001 |
| Education level | ||||
| None, n (%) | 2 (2) | 0 | 2 (3) | 0.658 |
| Primary education, n (%) | 71 (73) | 29 (74) | 42 (72) | 0.983 |
| Secondary education, n (%) | 22 (23) | 10 (26) | 12 (21) | 0.746 |
| Higher education, n (%) | 3 (3) | 0 | 2 (3) | 0.658 |
| Employment status | ||||
| Employed, n (%) | 45 (46) | 21 (54) | 24 (41) | 0.317 |
| Unemployed, n (%) | 20 (21) | 7 (18) | 13 (22) | 0.782 |
| Homemaker, n (%) | 17 (17) | 8 (20) | 9 (15) | 0.717 |
| Retired/pensioner, n (%) | 15 (15) | 3 (8) | 12 (21) | 0.147 |
| First-degree relatives with CD/FMS | ||||
| Subjects with CD relatives, n (%) | 10 (10) | 0 | 10 (17) | 0.016 |
| Subjects with FMS relatives, n (%) | 4 (4) | 0 | 4 (7) | 0.248 |
| Gastroduodenal histopathological details | ||||
| IELs, mean (SD) | 18 (3) | 14 (2) | 35 (5) | <0.001 |
| Helicobacter pylori (+), n (%) | 41 (42) | 17 (43) | 24 (41) | 0.426 |
| HLA haplotype | ||||
| HLA-DQ2 A1/B1, n (%) | 46 (47) | 15 (38) | 31 (53) | 0.214 |
| HLA-DQ2 (−), n (%) | 15 (15) | 4 (10) | 11 (19) | 0.381 |
| Serum autoantibodies | ||||
| Anti tTG-2, U/ml, mean (SD) | 0.7 (0.6) | 0.5 (0.1) | 0.9 (0.7) | <0.001 |
| RF, IU/m, mean (SD) | 12.8 (1.7) | 12.6 (0.9) | 12.9 (2.1) | 0.552 |
| Anti-TPO (+), U/ml, mean (SD) | 30 (111) | 20 (30) | 51 (140) | 0.115 |
| ANAs (+), n (%) | 26 (27) | 3 (8) | 23 (40) | 0.001 |
| AMAS (+), n (%) | 4 (4) | 0 | 4 (7) | 0.248 |
Data are expressed as frequency (n) and percentage of the total value (%), or mean and standard deviation (SD). BMI, body mass index; IELs, intraepithelial lymphocyte count from 100 epithelial cells; anti-tTG-2, anti-tissue transglutaminase-2 antibodies; RF, rheumatoid factor; HLA-DQ2, major histocompatibility complex class II; anti-TPO, anti-thyroid peroxidase antibodies; ANAs, anti-nuclear antibodies; AMAs, anti-mitochondrial antibodies.